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Abstract
Background: An estimated 17,000 patients are treated annually in the UK with radical radiotherapy (RT) for pelvic
cancer. New treatment approaches in RT have increased survivorship and changed the subjective toxicity profile for
patients who experience acute and long-term pelvic-related adverse events (AE). Multi-disciplinary follow-up creates
difficulty for monitoring and responding to these events during treatment and beyond. Originally developed for
use in systemic oncology therapy eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information
and aDvice) is an online system for patients to report AEs from home. eRAPID enables patient data to be integrated
into the electronic patient records for use in clinical practice, provides patient management advice for mild and
moderate AE and advice to contact the hospital for severe AE. The system has now been developed for pelvic RT
patients, and we aim to test the intervention in a pilot study with staff and patients to inform a future randomised
controlled trial (RCT).
Methods: Eligible patients are those attending St James’s University hospital cancer centre and The Christie
Hospital Manchester undergoing pelvic radiotherapy+/−chemotherapy/hormonotherapy for prostate, lower
gastrointestinal and gynaecological cancers. A prospective 1:1 randomised (intervention or usual care) parallel
group design with repeated measures and mixed methods will be employed. We aim to recruit 168 patients
following recommendations for sample size estimates for pilot studies. Participants using eRAPID will report AE (at
least weekly) from home weekly for 6 weeks and 6 weeks post-treatment (12-week total) then at 18 and 24 weeks.
Hospital staff will review eRAPID reports and use information during consultations. Notifications will be sent to the
relevant clinical team when severe symptoms are reported. We will measure patient-reported outcomes using
validated questionnaires (Functional Assessment in Cancer Therapy Scale-General (FACT-G), European Organisation
for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC-QLQ-C30), process of care impact
(hospital records of patient contacts and admissions) and economic variables (EQ5D-5L, patient use of resources)).
Staff and patient experiences will be explored via semi-structured interviews.
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Discussion: The objectives are to establish feasibility, recruitment, integrity of the system and attrition rates,
determine effect sizes and aid selection of the primary outcome measure for a future RCT. We will also refine the
intervention by exploring staff and patient views. The overall goal of this complex intervention is to improve the
safe delivery of cancer treatments, enhance patient care and standardise documentation of AE within the clinical
datasets.
Trial registration: ClinicalTrials.gov NCT02747264.
Keywords: Cancer, Adverse events, Patient-reported outcome measures (PROMs), Patient-reported outcomes (PROs),
Electronic, Electronic health records, Internet, Intervention, Self-management, Radiotherapy, Chemoradiotherapy
Background
An estimated 17,000 patients are treated annually in the
UK with radical radiotherapy (RT) for pelvic cancer [1].
New treatment approaches such as intensity-modulated
radiotherapy (IMRT), image-guided radiotherapy (IGRT),
fractionated delivery [2] and concomitant chemoradiother-
apy (chemoradiotherapy (CRT)) have changed the subject-
ive toxicity profile of radiotherapy (RT). Patients survive
longer but suffer acute and long-term pelvic-related AE.
Multi-disciplinary follow-up creates difficulty for monitor-
ing and responding to these events during treatment and
beyond [3]. In order to support patients and fully under-
stand the effects of new treatments, improved and more
timely documentation of acute, intermediate and late AE is
essential [4].
Prostate patients with localised cancer have good
long-term prognosis but endure the long-term effects of
pelvic RT [5]. In both cervical and ano-rectal cancer CRT
improves outcomes at the expense of additional chemo-
therapy specific toxicities and the late bowel, urinary and
sexual side effects from RT [6, 7]. Overall, for patients
treated with pelvic RT 59% women and 45% men will have
long-term gastrointestinal (GI) side effects, e.g. bowel
urgency [8]. Long-term genitourinary (GU) side effects
(e.g. urinary urgency) are experienced by 49% women and
46% men, and 24% women and 53% men state their ability
to have a sexual relationship is affected [8].
Assessment and documentation of RT-related AE is
generally inconsistent; therefore, improving the system-
atic and consistent recording of AE would inform strat-
egies to reduce the impact of AEs on patients, clinicians
and the health service [4, 6]. Late effects of pelvic RT
only fully develop and affect patients’ months/years
post-treatment, when centralised follow-up in specialised
RT clinics is often infrequent. A cost-effective model to
allow remote measurement of RT-AE would help pa-
tients to get appropriate specialist advice and support
when late toxicity emerges. Systematic data collection
would also allow comparisons and evaluation of the ben-
efits of new RT approaches.
In RT, AE are generally reported by clinicians using
the RTOG scale for acute AE and the Late Effects on
Normal Tissues–Subjective, Objective, Management and
Analytic (LENT-SOMA) [9]. Scale, which has been incor-
porated into the National Cancer Institute’s (NCI) Com-
mon Terminology Criteria for Adverse Events (CTCAE
v.3), now superseded by v.4 [10]. However, traditionally
clinician-reported AEs are heavily focussed on safety and
the rare more severe grades of toxicity.
Patient-reported outcomes (PROs)
Asking patients to report their own symptoms via
patient-reported outcomes (PROs) has proven ex-
tremely acceptable to patients in the oncology clinic
setting [10–13]. Reviews suggest they improve symp-
tom/function monitoring, physician patient communi-
cation, decision-making [14–19], timing and accuracy
of symptom reporting [20]. PROs have been increas-
ingly recommended by the United States Food and
Drug Administration (FDA) [21] and here in the UK
in the 2008 Darzi report [22]. The Department of
Health (DOH) subsequently produced guidelines to
aid their implementation [23], and we now have some
nationwide use of PROs in the NHS [24]. In terms of moni-
toring toxicity, the CTCAE scale has recently been adapted
for patients to self-report (NCI-PRO-CTCAE) [25, 26].
These items have concordance with nurse-evaluated AE
[27] and similar items created for self-report correlate with
quality of life (QOL) measures [28]. Increasingly, patients
are being asked to monitor their own health status
and self-manage symptoms. In response to this, we
have developed the eRAPID system to improve the
detection, and management of AE in cancer patients
by providing the means by which patients can report
symptoms from home [29, 30].
Electronic PROs (ePROs)
The use of ePROs in health research has risen exponen-
tially during the past 20 years for a number of conditions
including cancer [31, 32]. Patients have shown they can
routinely complete PROs electronically, [11] and paper
and electronic completions are comparable [33]. Further,
RT patients and staff said they would find an internet
PRO reporting tool acceptable. Clinicians thought this
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would improve their consultations with having graphical
representation of the PRO data [34]. It is also clear that
patients are willing and able to use PROs from home
internet or mobile devices [35, 36].
Examples of successful implementation of electronic
symptom reporting in oncology clinical practice include
PatientViewpoint [37], a flexible PRO platform, the
symptom tracking and reporting system (STAR) for pa-
tients to report chemotherapy AE [35], and the Tell Us™
[38] system for advanced cancer patients in hospices
undergoing palliative care (all in the USA). In Canada,
they have developed an interactive online system
(ISAAC) [39] and in the UK the ASyMS mobile phone
system [40]. Electronic patient-reported outcome sys-
tems have proven very acceptable even for patients cop-
ing with extreme symptom burden and reduced QOL;
indeed, a mean monthly PROM completion rate of 83%
at 34 weeks was achieved with patients receiving cancer
treatment [41]. In RT, the VisionTree Optimal Care
online reporting tool has proven acceptable to patients
and increased QOL completion compliance to 90% com-
pared to paper completion of 50% [42].
eRAPID development
In Leeds, we recently commissioned the development of
a web-based questionnaire builder system called QTool
(built by X-Lab, a private software company and funded
by Macmillan Cancer Support and Cancer Research UK)
(www.epocs.leeds.ac.uk). QTool Version1 was used in a
large prospective study of cancer survivors [43]; how-
ever, the PROs were not viewed by clinicians. Utilising
this technology eRAPID is an online system to support
the collection and clinical integration of patients’ symp-
tom/AE reports during cancer treatment [30]. Between
2010 and 2013, the eRAPID developmental work was
conducted (funded by a National Institute of Health
Programme Development Grant RP-DG-1209-10,031).
Developed originally for use in systemic treatment, the
system enables patients to report AE via PROs [44] and
the questionnaire data is integrated into the electronic
patient records (EPR) for clinicians to view. Algorith-
mic questionnaire scoring [44, 45] generates severity
dependent management advice to either call the hos-
pital or self-manage symptoms (accessible via a custom
build website). Currently, an RCT in systemic therapy
is underway recruiting 500 patients [46]. We have now
adapted the system for use in upper gastrointestinal
surgery and RT.
Multi-site eRAPID radiotherapy development
Developmental work was conducted to adapt the eRA-
PID system for RT in two centres (Leeds and The
Christie Hospital Manchester) and for patients under-
going pelvic radiotherapy for urological, gastrointestinal
and gynaecological cancer. A rigorous systematic ap-
proach was adopted according to the criteria for reporting
the development and evaluation of complex interventions
in healthcare [47] and the Medical Research Council
(MRC) guidelines [48].
In this two-centre study, professional and patient care
pathways and the role of eRAPID were explored via
audit and interviews with staff, patients and relatives
[49–51]. Additionally, we identified the AEs associated
with urological, gastrointestinal and gynaecological
cancers from patient interviews [50] and via systematic
reviews of PRO reporting for these groups [52–54]. In a
mapping exercise to matching questionnaire items to
common adverse events revealed the best questionnaire
coverage for adverse events for all tumour groups were
the male and female pelvic questionnaires (MPC and FPC)
[55]. For a clinical perspective Delphi (consensus method-
ology) was used with staff to make decisions on the most
appropriate items for each AE [56]. This led to the inclu-
sion of additional items from the EPIC (Expanded Prostate
Cancer Index) and the EORTC-QLQC-30 and PR 25 (pros-
tate module). In addition, to cover chemotherapy-related
AE items were taken from item pool developed for eRAPID
(systemic therapy) [44]. See (Additional file 1: Appendix 1)
for example of AE items used either as standard, branching
(having a prior qualifying question) or as a drop-down
(allowing selection of more appropriate options).
The AE questionnaires are scored according to specific
algorithms developed in consultation with key staff and
patients. Clinically meaningful cut scores for symptom
severity were developed through consenus and discus-
sion based methods [57]. The scorning and algorithms
allows the generation of severity-dependent management
advice for either mild (self-management advice), moder-
ate (self-management and advice to contact the hospital
when appropriate) or severe (advice to contact the hos-
pital immediately). The self-management advice for mild
level symptoms was developed from local and reputable
national resources [58] and uploaded to two designated
websites for Leeds and The Christie patients. AE. The
online system is now successfully implemented at Leeds
Teaching Hospitals NHS Trust (LTHT) and The Christie
Hospital Manchester.
The eRAPID intervention in radiotherapy
The developmental work led to the eRAPID complex
intervention [44, 46] consisting of the following compo-
nents (see Figs. 1 and 2):
 Patients login to QTool using unique usernames and
password and complete the eRAPID symptom
questionnaire from home on computers/mobile
phones/tablets or using designated kiosks (Leeds).
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Immediate tailored automated advice, calculated
from a series of algorithms, is generated.
 If severe symptoms are reported, patients are
advised to contact the hospital.
 For mild/moderate problem information about
self-managing, these issues are provided via brief
instructions in QTool and hyperlinks to more
detailed advice on the eRAPID RT patient
websites tailored to Leeds and The Christie local
information.
 The patient-reported data is immediately available
for staff to review in the individuals’ EPR in Leeds
Teaching Hospitals NHS Trust (PPM), The Christie
Clinical Web Portal (CWP).
 Notifications for severe symptom reports are sent
directly to staff via email. Clinicians can then
login to PPM and CWP and view the patients’
symptom reports and take appropriate action
where needed.
Aims and objectives
We aimed to conduct the initial pilot study of the eRA-
PID system in radiotherapy from the perspective of can-
cer patients and health professionals. The objectives are
to establish feasibility and determine effect sizes of the
potential benefits of the intervention for a future RCT.
The specific aims are to:
 Establish recruitment and attrition rates
 Establish adherence to symptom reporting and
record the number of calls made to the hospital by
patients
 Test the integrity of the study protocol and data
collection forms
 Test the integrity of information systems designed to
collect and collate the data
 Aid selection of the most appropriate primary
outcome measure and determine effect size
 Refine the intervention by exploring patient and staff
views.
Methods
Ethics
The study procedures below reflect the protocol version
1.3 as approved by the National Research Ethics Service
(now part of the Health Research Authority). The
approval was from Yorkshire & The Humber Leeds East
Research Ethics Committee on 13 September 2016 (REC
reference 16/YH/0371). Local approvals from the Leeds
Teaching Hospitals NHS Trust and The Christie Research
and Innovation Department were also obtained. Protocol
amendments will be communicated via written statements
and verbally reiterated where appropriate to the funder,
trial teams, clinicians, steering and project management
groups and trial registries.
Fig. 1 eRAPID system architecture overview
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Patient sample
The sample will include two groups of participants at
both The Christie Hospital Manchester (C) and Leeds
Teaching Hospitals NHS Trust (L):
1. Patients receiving radical RT for prostate cancer
(including radiotherapy for prostate cancer +/−
hormonotherapy+/− brachytherapy boost) (C & L).
2. Patients receiving pelvic chemoradiotherapy
including cervical (C & L), anal (C & L), rectal (L),
vaginal (L), vulval (C) and endometrial (C).
Inclusion criteria
Patients will be eligible if
– They have a diagnosis of (1) prostate cancer
requiring radical radiotherapy treatment (including
radiotherapy +/− brachytherapy boost) or (2) anal,
rectal, cervical, endometrial, vaginal or vulval cancer
requiring chemoradiotherapy.
– Aged 18 years or over.
– Attending St James’ University Hospital or The
Christie Hospital Manchester.
– Able and willing to give informed consent.
– Read and understand English have access to the
internet at home.
Exclusion criteria
Patients were excluded if taking part in other clinical tri-
als involving the completion of extensive PRO or QOL
measures or exhibiting overt psychopathology/cognitive
dysfunction.
Patient pathways
The chemoradiotherapy pathways (cervical, anal, rectal,
endometrial, vaginal and vulval patients) are very similar
at both centres. However, the cervical patients in Leeds
a
c
f g h
d e
b
Fig. 2 Screenshots of eRAPID intervention Patient login (a-f) a Login eRAPID portal, b access eRAPID websites for (QTool) login (Leeds and Manchester),
c login to online symptom report, d complete symptom report, e recieve advice to manage low-level symptoms, f login to online symptom report. Clinician
view of symptom reports in electronic patient record (EPR) (g & h) g symptom reports in EPR (tabular view), h symptom reports in EPR (grapical view)
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get a brachytherapy (BT) boost at 5 weeks and The
Christie patients undergo this at 6 weeks. At Leeds after
completion of radiotherapy, rectal patients (post-surgery)
are followed up by the surgeons. Patients will be encour-
aged to complete AE reporting for radiotherapy toxicity
but will be informed the surgical team will not be looking
at the patient-reported data at 12 and 24 weeks. However,
outcome measures will still be collected at 24 weeks. The
radical prostate treatment pathway is similar at both cen-
tres (The Christie and Leeds); however, The Christie offers
a 6-week follow-up via the telephone. All treatment path-
ways were mapped, and a detailed flow charts were made
including timelines, toxicities, treatment visits and health
personnel involved [59].
Comparability between centres
Although the Leeds and The Christie treatment sched-
ules differ slightly for each of the cancer sites, the treat-
ment volumes will be comparable. Similarly, the
timescales of toxicity will also be comparable, e.g. acute
bowel effects from pelvic RT usually start from 8th to
9th fraction, i.e. at end of the second week.
Design
This study is conducted at two centres (The Christie (C)
and Leeds (L) employing a prospective randomised
two-arm parallel group design with repeated measures
and mixed methods. Participants will be randomised to
either the intervention arm (eRAPID RT plus usual care)
or the control arm (usual care) with 1:1 allocation). See
Fig. 3 for the Trial Flow diagram.
eRAPID intervention
Only patients randomised to the intervention will
complete the eRAPID online symptom/AE report
within 24 h of study entry (forming the baseline symp-
tom report) and then weekly (or when experiencing
symptoms) for 12 weeks (6 weeks during treatment and
6 weeks post-treatment) and at 18 and 24 weeks.
Patients in the eRAPID intervention arm will also
complete self-efficacy and patient activation measures
and a questionnaire to assess their ability to use the on-
line system (system usability scale).
All patients (either eRAPID or usual care) complete
baseline measures (pre-randomisation) on paper and at
6, 12 and 24 weeks.
The timings of online completion and the outcome
measures were chosen based on the RT schedules and
the follow-up pathways, aiming to find a schedule of
completions that fits but allows for the slight differences
between the two centres.
Fig. 3 Trial flow diagram for the eRAPID radiotherapy feasibility pilot study
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Usual cancer care
Patients are provided with verbal and written information
on treatment benefits and expected AEs, and instructions
on how to manage AE and contact the hospital includ-
ing out-of-hours. They have a nurse/clinical oncologist/
radiographer assessment before starting treatment and
are given information on how to manage AE and
out-of-hours contact numbers.
Recruitment
Patients will be recruited from RT departments, out-
patient clinics and day-case wards at Leeds Teaching
Hospital NHS Trust and at The Christie Hospital Man-
chester (CHM). Eligible patients will be identified by
screening of clinic, in-patient or day-case lists by the
clinical or administration staff. Consultants responsible
for the care of patients are informed via letter or email.
After introduction from clinical staff, a researcher
(who has received Good Clinical Practice training (GCP)
will explain the study, provide an information sheet
(Additional file 1: Appendix 2) and obtain consent
(Additional file 1: Appendix 3) at this or the patient’s
next visit. Participants are free to withdraw from the trial
at any time without giving reasons and without preju-
dicing any further treatment. Reassurance is given that
anonymity will be maintained (patients are issued a study
number), and data collected will be treated in the
strictest confidence and held in accordance with the
Data Protection Act 1998.
Randomisation
Participants are randomised with 1:1 allocation to inter-
vention and control groups, performed centrally at the
University of Leeds Clinical Trials Research Unit
(CTRU) using the 24-h telephone system. Patients ran-
domised to the intervention arm receive training in
using the eRAPID system.
Patients are already stratified by cancer centre (Leeds
or Manchester) and will be further stratified by cancer
site, e.g. prostate or cancer requiring chemo RT (cervix,
anal, rectal, vaginal, endometrial and vulval). A diagram-
matic representation of the stratification factors is pre-
sented in Fig. 4.
Training
Staff
Staff are trained by the researchers reinforced by a
user-manual providing scenarios of an ‘example’ patient
and how to interact, interpret and access the PRO data
in the EPR and incorporate this data into their consulta-
tions. It is stressed that PRO data should be seen as a
supplementary resource to aid management decisions.
We will explore and reassure staff that using eRAPID
will not extend consultation times.
Patient
Researchers demonstrate how to use eRAPID system
and provide a unique user name and password to access
the system, on an eRAPID ‘postcard’. Participants are
given step-by-step user guide and if encounter problems
(e.g. lost user names/password or problems logging on)
are advised to contact the research team. Prompts to
complete the eRAPID questionnaire can be sent via
email or text message.
Sample size and recruitment rate
Thirty patients per arm for each treatment type will pro-
vide valuable information on outcomes [60] (Tables 1
and 2) Allowing for 30% overall attrition, we aim to re-
cruit a minimum of 42 patients per-arm (n = 84 for each
treatment type) at a rate of around 15 patients per
month for approximately 15 months giving an overall
total of 168 patients, with a 24-week follow-up.
Statistical analysis of the recruitment and attrition
rates, clinical process measures and patient outcome
data is the responsibility of the CTRU Trial Statistician
under the supervision of the Supervising Statistician. A
full statistical analysis plan has been written by the
CTRU Trial Statistician. A health economic data analysis
will be undertaken by a health economist from the aca-
demic Unit of Health Economics (AUHE), based on the
health economics analysis plan (HEAP). Interview data
will be processed by the research teams in the two
participating centres. All analyses will be conducted ac-
cording to the intention to treat (ITT) principle using
SAS statistical software.
Fig. 4 Stratification factors for eligible patients by hospital and cancer site
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Data collection and management
An overview of data to be collected during the study is
outlined in Tables 1 and 2.
Baseline assessments
All participants complete baseline questionnaires, in-
cluding socio-demographics and current computer
usage. Clinical baseline data will be obtained from par-
ticipants’ medical notes including sex, age, diagnosis,
co-morbidities, smoking status and planned treatment.
Patients will then be randomised to receive either usual
care or the eRAPID intervention (in addition to usual
care). Participants receiving the eRAPID intervention
will also be asked whether they want to receive re-
minders via email or text message to complete their
weekly online AE reports. Patients randomised to the
eRAPID arm will complete the first online report within
24 h as a baseline symptom report.
On-going online symptom reporting from home
Patient in the eRAPID arm will complete the AE symptom
report from home on a weekly basis during treatment (up
to 6 weeks) and for 6 weeks after (12 weeks in total).
Patient outcome measures
The following measures will be used to enable compari-
son between participants in the control and eRAPID
intervention arms and will be collected on paper.
Measures will be completed on paper at baseline then 6,
12 and 24 weeks from randomisation. The research team
will either provide the measures at routine hospital ap-
pointments or post them to participants (and provide
pre-paid envelopes for their return).
Use of resources form (completed at 6, 12 and 24 weeks)
Resource use will be assessed using a patient questionnaire
(detailing contacts with GPs/community services, hospital
visits), developed for a trial assessing treatment for
chemotherapy-related nausea/vomiting (http://journalsli-
brary.nihr.ac.uk/hta/hta17260). This has been revised for
use in RT from staff and patient input.
Quality of life and wellbeing
To assess the quality of life and wellbeing of the study
participants, the following validated measures will be
used as patient-reported outcomes:
EQ-5D-5L [61] (completed at baseline, 6, 12 and 24 weeks)
The EQ-5D is a standardised health outcome measure
developed by the EuroQol Group. EQ-5D has been used
with a range of health conditions and treatments provid-
ing a simple descriptive profile and single index value
for health status for use as part of a health economic
evaluation. The instrument assesses five dimensions:
mobility, self-care, usual activities, pain/discomfort and
anxiety/depression with five response levels (ranging
from no problems to extreme problems). The instru-
ment also includes a scale to rate health from 0 to 100
(worst-best health you can imagine).
Functional Assessment in Cancer Therapy Scale-General [62]
(FACT-G, completed at baseline, 6, 12 and 24 weeks)
The FACT-G is a cancer-specific measure widely used in
clinical trials. It has four subscales: physical wellbeing,
social or family wellbeing, emotional wellbeing, and
functional wellbeing. Question responses range from 0
to 4. Higher scores on the questionnaire indicate better
HRQL (score range, 0 to 108).
EORTC-QLQ-C30 [63] (completed at baseline, 6, 12 and
24 weeks)
The EORTC-QLQ-C30 is a 30-item questionnaire
consisting of five functional scales (physical, emotional,
cognitive, social, role), three symptom scales (fatigue,
pain, nausea/vomiting), a global health-related quality of
life scale and six single items (anorexia, insomnia,
dyspnoea, diarrhoea, constipation, financial difficulties).
Questions are rated on a 4 or 7-point response scale,
and overall scale scores are calculated from 0 to 100
with higher scores indicating better quality of life.
Table 1 eRAPID RT study questionnaires and Case Report
Forms (CRFs): researcher completed
Questionnaire/CRF Time point for completion
Eligibility checklist Baseline
Comorbidity form End of study
Consent form Baseline
Registration/randomisation form Baseline
Baseline: clinical data form End of study
Clinical process measures
Number of hospital contacts
Number of alerts and hospital
admissions
Readmissions (with reasons)
Clinician records of CTCAE
and RTOG
Changes to supportive medications
and RT and/or chemotherapy dose
changes
Contacts with GP/community services
Safety monitoring acute admissions,
cumulative deaths
Collected during a course of RT
treatment and if appropriate
chemotherapy cycle (from
hospital records and via brief
patient survey at routine clinic
appointments for interim
assessment of clinical contacts)
IT system functioning
Telephone log of phone calls
from patients
Record of unscheduled server
down time
Throughout the duration of
the study
Death and withdrawal form At point of death/withdrawal
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Self-efficacy and patient engagement in health care
Self-Efficacy for Managing Chronic Disease 6-Item
Scale [64, 65] (completed at baseline and 12 weeks)
This 6-item scale contains items taken from several
self-efficacy scales. It covers several domains common
across many chronic diseases such as symptom control,
role function, emotional functioning and communicating
with physicians.
The Patient Activation Measure [66] (PAM, completed at
baseline and 12 weeks)
The PAM is a tool for measuring the level of patient en-
gagement in their healthcare. The PAM 13-item scale
explores beliefs, knowledge and confidence for engaging
in health behaviours. Each item is rated on a four-point
scale from strongly disagree to strongly agree, and an
overall score from 0 to 100 can be calculated. These
scores can be subdivided to categorise people into one
of four activation categories ranging from 1-low activa-
tion to 4-high activation.
Patient satisfaction with the eRAPID technology
System Usability Scale [67] (SUS, completed at
24 weeks––eRAPID intervention arm only) The SUS
is a 10-item instrument to assess subjective views of us-
ability of different systems including hardware, software,
mobile devices, websites and applications. The 10 items
cover the ease of using the system, its complexity and
user confidence. Each item is rated from 1 to 5, and a
composite score of overall usability can be calculated
ranging from 0 to 100.
Clinical process measures
To assess any association between the eRAPID interven-
tion and improved detection and management of AEs,
Table 2 eRAPID RT study questionnaires and Case Report Forms (CRFs): participant completed
Questionnaire/CRF Description of time
points for completion
Baseline 3 weeks 6 weeks 9 weeks 12 weeks 18 weeks 24 weeks
Consent form Baseline X
Baseline: patient
sociodemographic
data form
Baseline X
Baseline: computer usage
questionnaire
Baseline X
Patient-reported eRAPID
symptom questionnaire
(eRAPID intervention
arm only)
Within 24 h of study entry
and weekly during treatment
and 6 weeks afterwards
(12 weeks total). Then at
18 and 24 weeks.
X weekly X weekly X weekly X weekly X weekly X (except
rectal)
X (except
rectal)
Patient Outcome Measures
FACT-G
EORTC-QLQ-C30
EQ-5D-5 L
Baseline, 6, 12 and 24 weeks X X X X
Self-efficacy, Lorig 6-item Baseline and 12 weeks X X
Patient Activation Measure
(PAM)
Baseline and 12 weeks X X
Use of resources form 6, 12 and 24 weeks X X X
System Usability Scale 24 weeks (eRAPID intervention
arm only)
X
Participant withdrawal
feedback form
At point of withdrawal
End of study patient questionnaire 24 weeks X
Clinician questionnaires
Clinician eRAPID feedback form
(eRAPID intervention arm only)
At routine hospital appointments
throughout the study
X X X X X (except
rectal)
X (except
rectal)
Clinician record of CTCAE To be completed by clinician at
the follow-up appointment
4–6 weeks after completion of
treatment (exact time-point will
be different for different disease
groups)
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the data will be collected from hospital triage forms,
medical records and hospital databases to record:
 Number of scheduled and unscheduled hospital
contacts (admissions, clinic visits, phone calls with staff)
 Changes to supportive medications, radiotherapy
regimens and chemotherapy dose changes
 Contacts with GP/district nurse/community services
 Number of clinician alerts generated from eRAPID
severe symptom reports and actions taken by staff.
In addition to the above, at routine radiotherapy re-
view, staff will be asked to provide:
 Clinician reports on use of eRAPID patient data
during consultations
 Clinician records of CTCAE matching those AE
questions completed by patients on the eRAPID
questionnaire at routine clinic visits at 4–6 weeks
after treatment completion (exact time-point will be
different for different disease groups)
End of study interviews and questionnaires
At the end of the study, a subset of patients and staff
will be interviewed and asked about their views of the
eRAPID system. All participants will be asked to
complete a short end of study questionnaire about their
experiences with the eRAPID intervention.
Participant interviews and questionnaires
At the end of the study, a purposive sample (by gender
and age) of up to 5 participants per disease group from
the intervention arm will be invited to interview. They
will be asked about the relevance and burden of com-
pleting routine PROMs throughout the study, and if the
eRAPID system had any impact on their care.
Where possible, participants who withdrew will be
asked to complete a voluntary brief feedback form to as-
sess potential reasons for withdrawal.
Staff interviews and questionnaires
Up to five health professionals from each disease group
will be interviewed at the end of the study to determine
their views of eRAPID, the perceived value and use of
patient data in clinical practice, exploring if eRAPID im-
proves the detection, documentation and management
of AE and support treatment decision-making. Percep-
tions of staff training needs and recommendations for
improving the system will also be explored.
Statistical analysis
Baseline characteristics
Data from the baseline socio-demographic, computer
usage and clinical data questionnaires will be tabulated
using frequencies and summary statistics for each treat-
ment group and overall.
Recruitment missing data and attrition
The feasibility of the recruitment strategy will be evaluated
by summarising the screening, eligibility and consent pro-
cesses, including the number of participants involved at
each stage. Where available, reasons for ineligibility and
non-participation in the study will be summarised. Reten-
tion during follow-up, including the number of partici-
pant’s withdrawing from the study and the timing of and
reasons for withdrawal will be presented. Acceptability
and potential conditions for improved acceptability will be
explored as part of the patient and staff interviews.
Clinical process measures
The number of telephone calls to hospital staff and
weekly/additional AE reports completed using the eRA-
PID system will be summarised. Clinician and staff ac-
ceptability will be explored during the staff interviews.
Initial interviews will determine any anticipated barriers
to the use of eRAPID, whereas exit interviews will
explore actual issues that prevented staff from incorpor-
ating information into routine practice. Clinicians will
be asked when and how they made use of the additional
information, and how this benefitted them.
Integrity of the study protocol and data collection forms
Any deviations from the study protocol, such as ineli-
gible patients being registered into the study, will be re-
ported. The time taken to complete the paper and
QTool forms and the amount of missing data will be
summarised.
Integrity of the information systems
Descriptive accounts of any issues with server downtime
leading to the unavailability of either the QTool ques-
tionnaire or patient-reported data in PPM and CWP will
be collected in order to evaluate the overall performance
and reliability of the IT system. If these are found to be
unacceptable, the relevant server hosts will be contacted.
Data from the participant phone call logs will be cate-
gorised to assess any common problems encountered
and to determine if any changes should be made to the
eRAPID training session/user guide to support partici-
pants more effectively. The System Usability Scale (SUS)
will be compared against available SUS scores for other
systems.
eRAPID system performance
Throughout the study, the eRAPID IT systems will be
monitored for unscheduled server down time (leading to
the unavailability of the QTool questionnaire website,
eRAPID website and patient symptom data in PPM and
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CWP). This is facilitated via a service level agreement
with University of Leeds IT services and protected by
the NHS firewall. The service provider is committed to
providing 99.9% uptime, and no unscheduled downtime
has occurred during the current study. Additionally, a log
of phone calls to the research team regarding issues/prob-
lems surrounding the use of eRAPID will be maintained.
Selection of patient outcome measures
Patient outcome measures (see Table 2) will be sum-
marised at each time point, and 95% confidence intervals
constructed for the differences between treatment arms.
In addition, the number of questionnaires completed
and the extent of missing data will be presented. To aid
selection for a future RCT, any ceiling and/or floor
effects from the questionnaires will be noted.
Health economic data
Patient-generated data based on the use of resources
form will be analysed descriptively for reported frequen-
cies of events and missing data. Comparisons will be
made between the number of hospital contacts and
admissions made by researchers with that provided by
patients.
Qualitative data
Interviews will be recorded and transcribed. Data will be
managed by NViVO software and analysed using thematic
analysis [68, 69]. To improve reliability and consistency
within the coding process, two researchers will independ-
ently conduct the analysis before meeting to discuss and
resolve inconsistencies. Understanding of the data will be
further refined by using constant comparison, contrastive
analysis and looking for negative cases.
Trial monitoring
Trial management group (TMG)
The TMG, comprising the Chief Investigator (CI),
Patient Reported Outcomes Group (POG) and the Ob-
servational and Supportive Team (OST) at The Christie,
patient representatives, CTRU team and other key exter-
nal members of staff involved in the trial will be assigned
responsibility for the clinical setup, on-going manage-
ment, promotion of the trial and for the interpretation
and publishing of the results. Specifically, (i) protocol
completion; (ii) case report form development; (iii)
obtaining approval from the main REC and supporting
applications for Site Specific Assessments; (iv) complet-
ing cost estimates and project initiation; (v) facilitating
the Trial Steering Committee (TSC); (vi) monitoring of
screening, recruitment, treatment and follow-up proce-
dures and (vii) auditing consent procedures, data collec-
tion, trial endpoint validation and database development.
Trial Steering Committee (TSC)
The independent Steering Committee for the overall
eRAPID programme will provide supervision of the RT
trial, in particular trial progress, adherence to protocol,
participant safety and consideration of new information.
In line with NIHR guidance, the TSC includes an Inde-
pendent Chair, three other independent members in-
cluding a patient representative. The Committee meets
in person annually as a minimum, with six monthly
meeting via teleconference. The TSC receives the TMG
reports and reports to the Sponsor and the funder
(NIHR). The CI and other members of the Trial Man-
agement Group (TMG) may attend the TSC meetings
and present and report progress. In addition, representa-
tives of the NIHR and of the Sponsor are invited to all
meetings and receive minutes.
Data monitoring (DMEC)
Routine data collection will be monitored for quality and
completeness in Leeds by POG and in Manchester by
the OST, using verification, validation and checking
processes. Missing data, except individual data items
collected from weekly symptom questionnaires, will be
chased until they are received or confirmed as not
available.
Any serious concerns about data will be referred to
the main trial data monitoring committee for systemic
therapy which is independent of the sponsor and com-
peting interests [45].
Safety monitoring plan
Monitoring acute admissions, cumulative deaths, cause
of death and other detrimental effects to patients will as-
sess the possibility of severe AEs being missed as a result
of the intervention. These will be reviewed monthly by
the CI, reported at each meeting of the TMG, and a
3-monthly report will be submitted for review to the
TSC. In addition, the CI will review on a monthly basis
patient-reported AE, note any serious reactions and
report where appropriate via the online Yellow card
scheme https://yellowcard.mhra.gov.uk.
Modifications
Research ethics committee (REC) will be sought for
modifications to the protocol, and any approved changes
will be communicated in written form (and reiterated
verbally) to all concerned parties including funders,
investigators, staff and trial participants registries and
regulators.
Clinical governance
The overall clinical responsibility and welfare of the
patients will remain with the individual treating clini-
cians within each disease group.
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Dissemination policy
The trial is registered with an authorised registry, ac-
cording to the International Committee of Medical Jour-
nal Editors (ICMJE) guidelines, prior to the start of
recruitment. Credit for the main results will be given to
all those who have collaborated in the trial, through
authorship and contributorship. Uniform requirements
for submission to medical journals will guide authorship
decisions. The CI, relevant research, CTRU and AUHE
staff will be named as authors in any publication. In
addition, all collaborators will be listed as contributors
for the main trial publication, giving details of roles in
planning, conducting and reporting the trial. To maintain
the scientific integrity of the trial, data will not be released
prior to the first publication of the analysis of the primary
endpoint, either for trial publication or oral presentation
purposes, without the permission of the TSC. In addition,
individual collaborators must not publish data concerning
their participants directly relevant to the questions posed in
the trial until the first publication of the analysis of the
primary endpoint. See Abbreviations below.
Discussion
This paper describes the protocol for the eRAPID feasibility
study in patients undergoing pelvic radiotherapy. eRAPID
is a complex web-based intervention designed to improve
the systematic reporting of AE during cancer treatment
and improve patient care and experiences. We aim to
determine the acceptability and feasibility from both the
perspective of patients undergoing pelvic radiotherapy+/−
chemo-radiotherapy and their health professionals to
determine effect sizes and select an appropriate outcome
measure for a future RCT. We also aim to refine the
intervention by exploring patient and staff views.
The immediate severity-related guidance generated from
eRAPID on how to manage AE is a unique feature of our
system compared to other ePRO web-portals [35, 38]. We
hypothesise that eRAPID will ultimately have benefits for
patients and staff. For patients, it may enable earlier symp-
tom detection and improved self-management, lead to
more timely admissions to manage more serious AE, im-
prove supportive medication use and appropriate health
service contacts. For staff, it may reduce the number of
contacts, save time spent on enquiring about and recording
AEs, focus attention and support decision-making during
consultations.
The ultimate success of eRAPID will depend on how pa-
tients and staff engage with and appreciate the potential
benefits of the system. This pilot study will determine the
acceptability and feasibility of the complex intervention
for patients and staff and determine any changes required
to improve the system prior to evaluation in an RCT. The
study is funded as part of 5-year programme and has the
potential to provide a cost-effective solution for follow-up
for pelvic radiotherapy patients by reducing hospital or
primary care contacts. In addition, it will help to create a
comprehensive database of RT AE and deliver vital PRO
information on treatments.
Additional file
Additional file 1: Appendix 1. Radiotherapy eRAPID symptom report
items. Appendix 2. Patient information sheet. Appendix 3. Patient consent
form. (DOCX 50 kb)
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